Robert Alain Toillon
, Professeur Université de Lille, INSERM U908, CPAC, Cell Plasticity and Cancer
Despite considerable progress in fundamental and clinical researches, current anti-cancer therapies consist mainly in tumor removal and/or destruction of the tumoral cells using radiotoxic and chemotoxic strategies. Unfortunately, cancers often become refractory to these treatments and patients are left with few or no treatment alternatives. Our objective is to better define molecular mechanisms driving tumor aggressiveness and therapy resistances. We aim to identify potential prognostic markers and to propose more efficient therapeutic strategies.